California [US], July 31 (ANI): A new study from Scripps Research suggests that some proof-of-concept HIV vaccines in early human trials generate antibodies that actively hinder protection by degrading the vaccine's payload.
California [US], July 29 (ANI): Some proof-of-concept HIV vaccines in early human trials generate antibodies that actively hinder protection by degrading the vaccine's payload, suggests a new study from Scripps Research.